Evidence map›Paper›PMID 24551118›Full record

ArticlePloS one2014

Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.

Pei-Ching Chang, Tao-Yeuan Wang, Yi-Ting Chang, Cheng-Ying Chu, Chin-Ling Lee, Hung-Wei Hsu, Tyng-An Zhou, Zhaoju Wu, Randie H Kim, Sonal J Desai and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. AMPK's double-faced role in advanced stages of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

Pei-Ching ChangInstitute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Tao-Yeuan WangDepartment of Pathology, Mackay Medical College and Mackay Memorial Hospital, New Taipei City, Taiwan, R.O.C ; Mackay Junior College of Medicine, Nursing, and Management, New Taipei City, Taiwan, R.O.C.
Yi-Ting ChangInstitute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Cheng-Ying ChuInstitute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, R.O.C.
Chin-Ling LeeDepartment of Pathology, Mackay Medical College and Mackay Memorial Hospital, New Taipei City, Taiwan, R.O.C ; Mackay Junior College of Medicine, Nursing, and Management, New Taipei City, Taiwan, R.O.C.
Hung-Wei HsuInstitute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Tyng-An ZhouInstitute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Zhaoju WuDepartment of Biochemistry and Molecular Medicine, University of California Davis, Davis, California, United States of America ; UC Davis Cancer Center, University of California Davis, Davis, California, United States of America.
Randie H KimDepartment of Dermatology, New York University School of Medicine, New York, New York, United States of America.
Sonal J DesaiUC Davis Cancer Center, University of California Davis, Davis, California, United States of America.
Shangqin LiuDepartment of Hematlogy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Hsing-Jien KungInstitute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, R.O.C ; Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California, United States of America ; Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, Taiwan, R.O.C.
National Yang Ming Chiao Tung University · TWUniversity of California, Davis · USMackay Junior College of Medicine, Nursing and Management · TWMackay Medical College · TWNew York University · USTaipei Medical University · TWUC Davis Comprehensive Cancer CenterWuhan University · CN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Prostate cancer (PCa) cells undergoing neuroendocrine differentiation (NED) are clinically relevant to the development of relapsed castration-resistant PCa. Increasing evidences show that autophagy involves in the development of neuroendocrine (NE) tumors, including PCa. To clarify the effect of autophagy on NED, androgen-sensitive PCa LNCaP cells were examined. Treatment of LNCaP cells with IL-6 resulted in an induction of autophagy. In the absence of androgen, IL-6 caused an even stronger activation of autophagy. Similar result was identified in NED induction. Inhibition of autophagy with chloroquine (CQ) markedly decreased NED. This observation was confirmed by beclin1 and Atg5 silencing experiments. Further supporting the role of autophagy in NED, we found that LC3 was up-regulated in PCa tissue that had relapsed after androgen-deprivation therapy when compared with their primary tumor counterpart. LC3 staining in relapsed PCa tissue showed punctate pattern similar to the staining of chromogranin A (CgA), a marker for NED cells. Moreover, autophagy inhibition induced the apoptosis of IL-6 induced NE differentiated PCa cells. Consistently, inhibition of autophagy by knockdown of beclin1 or Atg5 sensitized NE differentiated LNCaP cells to etoposide, a chemotherapy drug. To identify the mechanisms, phosphorylation of IL-6 downstream targets was analyzed. An increase in phospho-AMPK and a decrease in phospho-mTOR were found, which implies that IL-6 regulates autophagy through the AMPK/mTOR pathway. Most important to this study is the discovery of REST, a neuronal gene-specific transcriptional repressor that is involved in autophagy activation. REST was down-regulated in IL-6 treatment. Knockdown experiments suggest that REST is critical to NED and autophagy activation by IL-6. Together, our studies imply that autophagy is involved in PCa progression and plays a cytoprotective role when NED is induced in PCa cells by IL-6 treatment. These results reveal the potential of targeting autophagy as part of a combined therapeutic regime for NE tumors.

Indexed as

Adenylate KinaseAndrogensApoptosis Regulatory ProteinsAutophagyBeclin-1Cell DifferentiationCell Line, TumorChloroquineCytoprotectionDown-RegulationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansInterleukin-6MaleAdenylate KinaseAndrogensApoptosis Regulatory ProteinsBeclin-1BECN1 protein, humanChloroquineInterleukin-6Membrane ProteinsMTOR protein, humanRE1-Silencing Transcription FactorRepressor ProteinsTOR Serine-Threonine Kinases

Identifiers

PMID24551118
PMCPMC3925144
OpenAlexW2085615042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.